ライフサイエンスコーパス: pelvic organ prolapse

1 c organ prolapse compared with those without pelvic organ prolapse.

2 performed annually in the United States for pelvic organ prolapse.

3 o discuss the epidemiology and prevalence of pelvic organ prolapse.

4 revention in patients at risk for developing pelvic organ prolapse.

5 transvaginal mesh kits for the treatment of pelvic organ prolapse.

6 al pelvic floor for defecatory disorders and pelvic organ prolapse.

7 have increased the available treatments for pelvic organ prolapse.

8 9% of women (95% CI, 2.1%-3.7%) experiencing pelvic organ prolapse.

9 important components in the pathogenesis of pelvic organ prolapse.

10 ions in lysyl oxidase-like 1 (LOXL1) develop pelvic organ prolapse.

11 nt of female stress urinary incontinence and pelvic organ prolapse.

12 in repair of stress urinary incontinence and pelvic organ prolapse.

13 rinary incontinence, fecal incontinence, and pelvic organ prolapse) affect many women.

14 rformed to determine the association between pelvic organ prolapse and exfoliation syndrome in women

15 ant proven benefit for symptomatic relief of pelvic organ prolapse and improvement of quality of life

16 free vaginal tape was examined in women with pelvic organ prolapse and older in age.

17 of conditions affecting adult women, include pelvic organ prolapse and urinary incontinence.

18 Many women with pelvic organ prolapse are asymptomatic and do not need t

19 incontinence undergoing vaginal surgery for pelvic-organ prolapse are at risk for postoperative urin

20 than 90% of fibulin-5-knockout mice develop pelvic organ prolapse by 20 weeks of age.

21 of life impact of PFD, total and by domain (pelvic organ prolapse, colorectal-anal, and urogenital).

22 the exfoliation syndrome risk in women with pelvic organ prolapse compared with those without pelvic

23 The surgical management of pelvic organ prolapse continues to evolve.

24 bdominal sacrocolpopexy for the treatment of pelvic-organ prolapse decreases postoperative stress uri

25 en aged 30 to 65 years at baseline who had a pelvic organ prolapse diagnosis compared with controls d

26 mes at 2 years were prolapse symptom scores (Pelvic Organ Prolapse Distress Inventory; range 0-300, h

27 omain (P = 0.0005, 95% CI: 3.8-13.5) and the pelvic organ prolapse domain (P = 0.015, 95% CI: 0.6-9.5

28 in the uterine tract post partum and develop pelvic organ prolapse, enlarged airspaces of the lung, l

29 trials that included surgical operations for pelvic organ prolapse for this review.

30 o the assessment of defecatory disorders and pelvic organ prolapse has highlighted the limitations of

31 Pelvic organ prolapse in Fbln5-/- mice was remarkably si

32 life expectancy increases, the prevalence of pelvic organ prolapse in general, and rectoceles, in par

33 is is a primary event in the pathogenesis of pelvic organ prolapse in mice.

34 ion syndrome was more frequent in women with pelvic organ prolapse in the Utah Population Database, a

35 ific quantificative information about female pelvic organ prolapse-information that usually can only

36 Pelvic organ prolapse is a common connective tissue diso

37 Pelvic organ prolapse is closely related to SUI, and the

38 Pelvic organ prolapse is common and is strongly associat

39 Pelvic organ prolapse is downward descent of female pelv

40 Pelvic organ prolapse is strongly associated with a hist

41 thought to be involved in the development of pelvic organ prolapse may also be linked to the developm

42 ditions with altered ECM metabolism, such as pelvic organ prolapse, may share common biological pathw

43 d women serving as controls who did not have pelvic organ prolapse (n = 15338).

44 to 65 years at baseline with a diagnosis of pelvic organ prolapse (n = 5130) compared with birth yea

45 full understanding of the complex impact of pelvic organ prolapse on lower urinary tract function is

46 lastic fiber assembly in the pathogenesis of pelvic organ prolapse, pelvic organ support was characte

47 rders, a large portion of which will involve pelvic organ prolapse (POP) and lower urinary tract dysf

48 for the fibulin-5 gene (Fbln5(-/-)) develop pelvic organ prolapse (POP) due to compromised elastic f

49 Pelvic organ prolapse (POP) is a common condition affect

50 Pelvic organ prolapse (POP) is a common, debilitating di

51 Pelvic organ prolapse (POP) is a disabling disorder in w

52 Mesh, a synthetic graft, has been used in pelvic organ prolapse (POP) repair and stress urinary in

53 PURPOSE OF REVIEW: Mesh used for slings and pelvic organ prolapse (POP) repair has resulted in incre

54 y have continually adapted new techniques in pelvic organ prolapse (POP) repair in order to improve b

55 uation of the use of commercial mesh kits in pelvic organ prolapse (POP) repair.

56 ublished data concerning the indications for pelvic organ prolapse (POP) surgery in women who present

57 OF REVIEW: As more women undergo repairs of pelvic organ prolapse (POP), an ever-increasing scrutiny

58 for pelvic floor disorders (PFDs), including pelvic organ prolapse (POP), stress urinary incontinence

59 performed annually in the United States for pelvic organ prolapse (POP).

60 nimally invasive surgery in the treatment of pelvic organ prolapse (POP); however, the robotic indust

61 hile the introduction of novel approaches to pelvic organ prolapse provide further options when consi

62 natomic POP failure requiring retreatment or Pelvic Organ Prolapse Quantification evaluation demonstr

63 anterior prolapse (of stage 2 or higher on a Pelvic Organ Prolapse Quantification system examination)

64 Using the Pelvic Organ Prolapse Quantification system, researchers

65 mesh use in stress urinary incontinence and pelvic organ prolapse repair are examined.

66 search (basic and clinical) are post-MUS and pelvic organ prolapse repair urinary retention and obstr

67 y become the preferred approach to abdominal pelvic organ prolapse repair.

68 outcomes of different vaginal approaches to pelvic organ prolapse repair.

69 able using minimally invasive techniques for pelvic organ prolapse repair.

70 ry vulnerable to surgical techniques used in pelvic organ prolapse repair.

71 kage of solid, liquid, or mucous stool), and pelvic organ prolapse (seeing/feeling a bulge in or outs

72 Defining a successful outcome of pelvic organ prolapse surgery from a symptomatic perspec

73 RECENT FINDINGS: Success in pelvic organ prolapse surgery has been redefined.

74 h require a review of vaginal approaches for pelvic organ prolapse surgery with and without mesh.

75 out how to define a successful outcome after pelvic organ prolapse surgery.

76 icipant-reported prolapse symptoms (i.e. the Pelvic Organ Prolapse Symptom Score [POP-SS]) and condit

77 ie, a significantly greater reduction in the pelvic organ prolapse symptom score [POP-SS]) at 12 mont

78 outcome was self-reported prolapse symptoms (Pelvic Organ Prolapse Symptom Score [POP-SS]) at 2 years

79 of concomitant conditions, such as advanced pelvic organ prolapse, that may require referral.

80 association between exfoliation syndrome and pelvic organ prolapse using the Utah Population Database

81 surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh.

82 Pelvic organ prolapse was associated with a 1.56-fold in

83 ndrome (exfoliation of the lens capsule) and pelvic organ prolapse was investigated as part of the Ut

84 ersy regarding the use of synthetic mesh for pelvic organ prolapse, we did a retrospective review of

85 ho will present to healthcare providers with pelvic organ prolapse, we need a better understanding of

86 elastic fibers after parturition, leading to pelvic organ prolapse, weakening of the vaginal wall, pa

87 ontinence (11%), non-injury wounds (9%), and pelvic organ prolapse were also prevalent.

88 pected to double in number by the year 2030, pelvic organ prolapse will become more prevalent.

89 t exfoliation syndrome risk in patients with pelvic organ prolapse (without exfoliation syndrome hist